Thursday 25 August 2016

Scientists discover drug combination slows lung cancer cell growth

A study shows that a drug combination slows cancer cell growth in a type of non small cell lung cancer when tested in the lab, offering potential for developing new treatments in the future, according to a Cancer Research UK funded study published in the British Journal of Cancer today.

The drug combination delivers a double whammy to the way the KRAS gene makes cancer cells grow. KRAS is estimated to be mutated in 15 to 25 per cent of people with non-small cell lung adenocarcinomas.

Read more at Cancer Research UK.

Study mentioned:
Sophie Broutin, Adam Stewart, Parames Thavasu, Angelo Paci, Jean-Michel Bidart and Udai Banerji. Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. Br J Cancer 115: 549-552; doi:10.1038/bjc.2016.220 (link is external)


No comments:

Post a Comment